Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290570 · ClinicalTrials.gov registry record
A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's
A clinical trial of Hypertrophic Cardiomyopathy, sponsored by Mayo Clinic.
- Active
- Registry status
- 183
- Enrollment target
- 1
- Study location
NCT06290570: Active study of Hypertrophic Cardiomyopathy, sponsored by Mayo Clinic.
NCT06290570 is a study of Hypertrophic Cardiomyopathy that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 183 participants, below the 1,333-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290570, a study of Hypertrophic Cardiomyopathy, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 183 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor KardiaMobile devices.
Primary Outcome
Artificial Intelligence (AI) scores will be measured using the AI Algorithm on ECG tracings obtained from clinically indicated 12-Lead ECG, Apple Smart Watch (single-lead), and AliveCor KardiaMobile (6-Lead) in subjects with HCM. The AI scores will be utilized to generate the AI-ECG probability of accurately diagnosing HCM (labelled as true positive, true negative, false positive, false negative) and the distribution of AI-ECG probabilities will be evaluated. A higher distribution of AI-ECG prob
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 12-Lead ECG
- DIAGNOSTIC_TEST Apple Smart Watch Single Lead ECG
- DIAGNOSTIC_TEST AliveCor KardiaMobile 6-Lead ECG
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2026-12 |
What the registry record for NCT06290570 still lists
NCT06290570 is an observational study that tracks outcomes without assigning an intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 1,333-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 3 interventions - of which 12-Lead ECG is the first listed.
NCT06290570 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06290570 about?
NCT06290570 is a clinical study titled "A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's". The purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor KardiaMobile devices.
What is the current status of trial NCT06290570?
This trial is currently active not recruiting. The enrollment target is 183 participants. The study started on 2024-05-07. Estimated completion is 2026-12.
What conditions does trial NCT06290570 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06290570?
The interventions under investigation include: 12-Lead ECG (DIAGNOSTIC_TEST), Apple Smart Watch Single Lead ECG (DIAGNOSTIC_TEST), AliveCor KardiaMobile 6-Lead ECG (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06290570?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290570 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06290570's enrollment target sits among peer trials
183 7th of 10 higher than 4 of 10 other Hypertrophic Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertrophic Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
VIZ ACCESS HCM - Multi-Site Registry
RECRUITING
-
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
RECRUITING · NA
-
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
RECRUITING · Phase 1
-
Mavacamten Pregnancy Surveillance Program
RECRUITING
-
Pediatric Cardiomyopathy Mutation Analysis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI